Calcific uraemic arteriolopathy: an update
- 1 November 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Nephrology and Hypertension
- Vol. 17 (6), 629-634
- https://doi.org/10.1097/mnh.0b013e32830f4566
Abstract
Copyright © 2008 Lippincott Williams & Wilkins, Inc.PURPOSE OF REVIEW: Calcific uraemic arteriolopathy (CUA) or calciphylaxis is a rare but important cause of morbidity and mortality in patients with chronic kidney disease. The prevalence of CUA is increasing in patients with renal failure, and the condition is also being recognized in nonuraemic patients. RECENT FINDINGS: There has been increasing understanding of the molecular basis of vascular calcification, in particular on the important role of the uraemic microenvironment in the factors implicated in the differentiation of vascular smooth muscle cells into osteoblasts. New options for treatment of hyperphosphataemia and secondary hyperparathyroidism in patients with chronic kidney disease have become available in the last few years and these have begun to be used in patients with CUA. These include bisphosphonates, newer noncalcium/nonaluminium-containing phosphate binders and case reports of use of cinacalcet. Other treatments for CUA that are not targeted directly at calcium/phosphate homeostasis include hyperbaric oxygen and the antioxidant cation chelator sodium thiosulphate. SUMMARY: Clinicians managing patients with CUA should consider a combination approach of treating deranged calcium/phosphate with newer therapeutic agents and promoting wound healing with other older modalities such as hyperbaric oxygen and sodium thiosulphate infusions. Randomized controlled trials for treatments in CUA are still lacking.Rogers, Natasha M; Coates, Patrick TobyKeywords
This publication has 55 references indexed in Scilit:
- Calciphylaxis: Emerging Concepts in Prevention, Diagnosis, and TreatmentSeminars in Dialysis, 2002
- Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapyKidney International, 2002
- Risk factors and mortality associated with calciphylaxis in end-stage renal diseaseKidney International, 2001
- Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cellsAmerican Journal of Kidney Diseases, 2001
- Transcutaneous oxygen tension in patients with calciphylaxisAmerican Journal of Kidney Diseases, 2001
- Acute Respiratory Failure due to ‘Pulmonary Calciphylaxis’ in a Maintenance Haemodialysis PatientNephron, 2001
- Rhabdomyolysis as the presenting manifestation of calciphylaxisMuscle & Nerve, 2000
- A case control study of proximal calciphylaxisAmerican Journal of Kidney Diseases, 1998
- Calciphylaxis in patients on hemodialysis: A prevalence studySurgery, 1997
- Systemic calciphylaxis presenting as a painful, proximal myopathyPublished by Oxford University Press (OUP) ,1992